Greta A Bushnell1, Mark Olfson2, Silvia S Martins3. 1. Department of Epidemiology, Columbia University Mailman School of Public Health, 722 W 168(th) St., New York, NY 10032, United States. Electronic address: gbushnell@ifh.rutgers.edu. 2. Department of Epidemiology, Columbia University Mailman School of Public Health, 722 W 168(th) St., New York, NY 10032, United States; Department of Psychiatry, Columbia University Irving Medical Center, 1051 Riverside Dr., New York, NY 10032, United States. 3. Department of Epidemiology, Columbia University Mailman School of Public Health, 722 W 168(th) St., New York, NY 10032, United States.
Abstract
BACKGROUND: Benzodiazepine (BZD)-related overdose deaths have risen in the past decade and BZD misuse contributes to thousands of emergency department (ED) visits annually, with the highest rates in adolescents and young adults. Because there are gaps in understanding BZD poisoning in youth and whether differences occur by sex, we aimed to characterize BZD poisoning ED visits in young people by sex. METHODS: BZD poisoning visits were identified in the Nationwide Emergency Department Sample, among adolescents (12-17 years) and young adults (18-29 years). Stratified by sex and age, we described ED visits for BZD poisonings in 2016, including poisoning intent, concurrent substances involved, and co-occurring mental health disorder diagnoses. With logistic regression we examined the association between intent and concurrent substance. RESULTS: There were approximately 38,000 BZD poisoning ED visits by young people nationwide with annual population rates per 10,000 of 2.9=adolescents and 5.8=young adults. Depression was diagnosed in 40 % of female and 23 % of male BZD visits (p < 0.01). Over half of BZD poisonings in females and a third in males were intentional (p < 0.01). Male BZD visits were more likely to involve opioids or cannabis and less likely to involve antidepressants than females (p-values<0.01). In males and females, BZD poisonings concurrent with antidepressants and other psychotropic medications were more likely to be intentional than unintentional (OR range:2.1-6.3). CONCLUSIONS: The high proportion of BZD poisonings that are intentional and include mental health disorder diagnoses, especially among young females, underscore the importance of ED mental health and suicide risk assessment with appropriate follow-up referral.
BACKGROUND: Benzodiazepine (BZD)-related overdose deaths have risen in the past decade and BZD misuse contributes to thousands of emergency department (ED) visits annually, with the highest rates in adolescents and young adults. Because there are gaps in understanding BZD poisoning in youth and whether differences occur by sex, we aimed to characterize BZD poisoning ED visits in young people by sex. METHODS: BZD poisoning visits were identified in the Nationwide Emergency Department Sample, among adolescents (12-17 years) and young adults (18-29 years). Stratified by sex and age, we described ED visits for BZD poisonings in 2016, including poisoning intent, concurrent substances involved, and co-occurring mental health disorder diagnoses. With logistic regression we examined the association between intent and concurrent substance. RESULTS: There were approximately 38,000 BZD poisoning ED visits by young people nationwide with annual population rates per 10,000 of 2.9=adolescents and 5.8=young adults. Depression was diagnosed in 40 % of female and 23 % of male BZD visits (p < 0.01). Over half of BZD poisonings in females and a third in males were intentional (p < 0.01). Male BZD visits were more likely to involve opioids or cannabis and less likely to involve antidepressants than females (p-values<0.01). In males and females, BZD poisonings concurrent with antidepressants and other psychotropic medications were more likely to be intentional than unintentional (OR range:2.1-6.3). CONCLUSIONS: The high proportion of BZD poisonings that are intentional and include mental health disorder diagnoses, especially among young females, underscore the importance of ED mental health and suicide risk assessment with appropriate follow-up referral.
Authors: Carlos Blanco; Beth Han; Christopher M Jones; Kimberly Johnson; Wilson M Compton Journal: J Clin Psychiatry Date: 2018-10-16 Impact factor: 4.384
Authors: Sean Esteban McCabe; Timothy E Wilens; Carol J Boyd; Kao-Ping Chua; Terri Voepel-Lewis; Ty S Schepis Journal: Addict Behav Date: 2018-11-14 Impact factor: 3.913
Authors: Ivan W Miller; Carlos A Camargo; Sarah A Arias; Ashley F Sullivan; Michael H Allen; Amy B Goldstein; Anne P Manton; Janice A Espinola; Richard Jones; Kohei Hasegawa; Edwin D Boudreaux Journal: JAMA Psychiatry Date: 2017-06-01 Impact factor: 21.596
Authors: George C Patton; Susan M Sawyer; John S Santelli; David A Ross; Rima Afifi; Nicholas B Allen; Monika Arora; Peter Azzopardi; Wendy Baldwin; Christopher Bonell; Ritsuko Kakuma; Elissa Kennedy; Jaqueline Mahon; Terry McGovern; Ali H Mokdad; Vikram Patel; Suzanne Petroni; Nicola Reavley; Kikelomo Taiwo; Jane Waldfogel; Dakshitha Wickremarathne; Carmen Barroso; Zulfiqar Bhutta; Adesegun O Fatusi; Amitabh Mattoo; Judith Diers; Jing Fang; Jane Ferguson; Frederick Ssewamala; Russell M Viner Journal: Lancet Date: 2016-05-09 Impact factor: 79.321
Authors: Ted R Miller; David I Swedler; Bruce A Lawrence; Bina Ali; Ian R H Rockett; Nancy N Carlson; Jennifer Leonardo Journal: JAMA Netw Open Date: 2020-03-02
Authors: Gema Castillo-Sánchez; Mario Jojoa Acosta; Begonya Garcia-Zapirain; Isabel De la Torre; Manuel Franco-Martín Journal: Int J Ment Health Addict Date: 2022-07-18 Impact factor: 11.555